von Willebrand factor A domain containing 2Genealiases: AMACO · CCSP-2 · CCSP2 · NET42
Q-omics provides the consensus-scored VWA2 profile across patient tissues and cancer cell-line models. VWA2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, VWA2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, VWA2 RNA expression shows 17,843 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where VWA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VWA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VWA2 survival associations across molecular data types. VWA2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VWA2 RNA expression–survival associations across cancer types. High VWA2 expression shows unfavorable associations in UVM and LUSC, but favorable associations in LUAD, KIRP, BRCA and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for VWA2 RNA expression.
This table summarizes VWA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VWA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VWA2 shows lower tumor expression in KIRC, HNSC, KICH and LUSC and higher tumor expression in COAD and LUAD. The KIRC box plot shows higher VWA2 RNA expression in normal versus tumor tissue (log2 FC = −1.767, t-test p < 0.001).
This table shows molecular features associated with VWA2 in patient tissues and cancer cell lines. In patient samples, VWA2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, VWA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_NSCLC_LUAD.
